Protalix BioTherapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Protalix BioTherapeutics CEO'su Dror Bashan, Jun2019 tarihinde atandı, in görev süresi 5.42 yıldır. in toplam yıllık tazminatı $ 2.68M olup, şirket hissesi ve opsiyonları dahil olmak üzere 13.3% maaş ve 86.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.1% ine doğrudan sahiptir ve bu hisseler $ 2.92M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.3 yıl ve 5.1 yıldır.

Anahtar bilgiler

Dror Bashan

İcra Kurulu Başkanı

US$2.7m

Toplam tazminat

CEO maaş yüzdesi	13.3%
CEO görev süresi	5.4yrs
CEO sahipliği	3.1%
Yönetim ortalama görev süresi	5.3yrs
Yönetim Kurulu ortalama görev süresi	5.1yrs

Son yönetim güncellemeleri

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Jan 14

Recent updates

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Feb 22

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Jan 14

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Dec 10

CEO Tazminat Analizi

Dror Bashan'un ücretlendirmesi Protalix BioTherapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$15m
Mar 31 2024	n/a	n/a	US$7m
Dec 31 2023	US$3m	US$357k	US$8m
Sep 30 2023	n/a	n/a	US$11m
Jun 30 2023	n/a	n/a	US$9m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$1m	US$360k	-US$15m
Sep 30 2022	n/a	n/a	-US$18m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$374k	-US$28m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$1m	US$352k	-US$7m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	US$566k	US$175k	-US$18m

Tazminat ve Piyasa: Dror 'nin toplam tazminatı ($USD 2.68M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.78K ).

Tazminat ve Kazançlar: Dror şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Dror Bashan (57 yo)

5.4yrs

Görev süresi

US$2,684,941

Tazminat

Mr. Dror Bashan has been President, Chief Executive Officer and Director of Protalix BioTherapeutics, Inc. since June 30, 2019. He has experience in the pharmaceutical industry with roles ranging from busi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dror Bashan	President	5.4yrs	US$2.68m	3.1% $ 2.9m
Eyal Rubin	Senior VP	5.2yrs	US$1.03m	0.91% $ 856.3k
Yaron Naos	Senior Vice President of Operations	6.5yrs	US$776.37k	0.28% $ 265.3k
Yael Fellous	Vice President of Human Resources	2.3yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: PLX 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dror Bashan	President	5.4yrs	US$2.68m	3.1% $ 2.9m
Amos Shalev	Independent Director	16.3yrs	US$79.91k	0.00023% $ 216.5
Aharon Schwartz	Independent Director	10yrs	US$79.91k	0.24% $ 222.7k
Gwen A. Melincoff	Independent Director	4.8yrs	US$79.91k	Veri yok
Charles Arntzen	Member of Scientific Advisory Board	8.4yrs	Veri yok	Veri yok
Alexander Levitzki	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Shmuel Ben-Zvi	Independent Director	2.4yrs	US$74.71k	Veri yok
Roger Kornberg	Chairman of Scientific Advisory Board	no data	US$55.00k	Veri yok
Eliot Forster	Independent Chairman	1.2yrs	US$47.99k	Veri yok
Pol Boudes	Independent Director	4.8yrs	US$115.39k	0.000050% $ 47.1

5.1yrs

Ortalama Görev Süresi

71.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PLX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.1 yıldır).

Protalix BioTherapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

President recently bought US$102k worth of stock

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Recent updates

Protalix BioTherapeutics, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Protalix BioTherapeutics, Inc.(NYSEAM:PLX) dropped from Russell Small Cap Comp Value Index

Protalix BioTherapeutics, Inc. to Report Q1, 2024 Results on May 10, 2024

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 27, 2024

Protalix BioTherapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Protalix BioTherapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Protalix Biotherapeutics Appoints Eliot Richard Forster to Succeed Zeev Bronfeld as Chairman, Effective as of September 14, 2023

Protalix BioTherapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Protalix BioTherapeutics, Inc., Annual General Meeting, Jun 28, 2023

Chiesi Global Rare Diseases and Protalix Biotherapeutics, Inc. Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease

Protalix Biotherapeutics, Inc. and Chiesi Global Rare Diseases Announces European Commission Grants Marketing Authorization to PRX-102 (Pegunigalsidase Alfa) for the Treatment of Adult Patients with Fabry Disease

Protalix BioTherapeutics to Delist Its Common Stock from the Tel Aviv Stock Exchange

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of A Resubmitted Biologics License Application for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Consensus revenue estimates increase by 20%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Protalix BioTherapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Protalix BioTherapeutics, Inc. Appoints Shmuel "Muli" Ben Zvi to Its Board of Directors and Audit Committee and Compensation Committee

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$9.00

President recently bought US$102k worth of stock

Protalix Biotherapeutics, Inc. Announces Topline Results from BALANCE Pivotal Phase III Clinical Trial Evaluating pegunigalsidase alfa

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Submission of Marketing Authorization Application to the European Medicines Agency for PRX-102 for Treatment of Fabry Disease

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.25 loss per share (vs US$0.13 loss in 2Q 2020)

Protalix BioTherapeutics, Inc. Announces Submission of Type A Meeting Request to the FDA

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Provide Update Regarding Clinical Development of PRX-102 for Treatment of Fabry Disease

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.096 profit in 1Q 2020)

Forecast breakeven pushed back to 2022

Protalix Biotherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from Fda

Full year 2020 earnings released: US$0.22 loss per share (vs US$1.23 loss in FY 2019)

Protalix BioTherapeutics, Inc. and Chiesi Global Rare Diseases Announces Positive Topline Results from Bright Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa 2 Mg/Kg Every Four Weeks for Treatment of Fabry Disease

Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon

Protalix Biotherapeutics Enters into an Exclusive Partnership with Sarcomed USA to Develop Alidornase Alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled Delivery

Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.91

Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021

New 90-day high: US$4.17

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announce Final Results of Bridge Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?

Protalix Biotherapeutics and Chiesi Global Rare Diseases Announces Extension of Pdufa Date for Pegunigalsidase Alfa for the Propose Treatment of Fabry Disease

New 90-day high: US$3.96

Third quarter earnings released

Third-quarter earnings released: Earnings miss expectations

New 90-day low: US$3.35

Chiesi Farmaceutici S.P.A. and Protalix BioTherapeutics, Inc Announce Launch of an Expanded Access Program (Eap) in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease

Protalix Biotherapeutics and Chiesi Farmaceutici Announce Successful Pre-BLA Meeting with FDA for Accelerated Approval of Pegunigalsidase Alfa for the Treatment of Fabry Disease in the United States

New 90-day low - US$3.37

Protalix Biotherapeutics Regains Compliance with NYSE American Continued Listing Standards

Price target lowered to US$9.75

First half earnings released

Protalix BioTherapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş